parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in pituicytes/fscs	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 113	0.85
pathways Reactome	1 pathway; mostly growth signalling	0.60

No case: the score is under the bar. Receipt 12717

MAPK4 in dopamine neurons, braak-0.18 (p 0.646) → -0.24 (p 0.537)receipt 12725
MAPK4 in astrocytes, braak+0.16 (p 0.685) → +0.11 (p 0.787)receipt 12724

receipt 12725: MAPK4 in dopamine neurons, braak

power: full sample -0.07 (p 0.774, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.12 (p 0.646, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.36 (p 0.142, n 18). could be the mix.
skeptic: leave-one-out range -0.20 to +0.06, sign flips 4; without severely affected donors -0.07 (p 0.774, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAPK4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12724: MAPK4 in astrocytes, braak

power: full sample +0.09 (p 0.728, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.14 (p 0.579, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.13 (p 0.621, n 18). could be the mix.
skeptic: leave-one-out range -0.04 to +0.20, sign flips 3; without severely affected donors +0.09 (p 0.728, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAPK4 in astrocytes.

case closed: nothing better to follow up.

loading the receipts